Zydus Cadila COVID-19 Vaccine Found Safe in Clinical Trials

In the phase I and II clinical trials, Zydus Cadila announced that its plasmid DNA vaccine to prevent COVID-19 - ZyCoV-D - was found to be safe, well tolerated and immunogenic.

In the phase I and II clinical trials, Zydus Cadila announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D, was found to be safe, well tolerated and immunogenic.

The company is now planning to initiate phase III clinical trial in around 30,000 volunteers upon receiving necessary approvals.

What Makes People Motivated to Get COVID-19 Vaccine
People are consistently more likely to be vaccinated when their prosocial concerns are higher, i.e., they encounter more people and have a greater risk of transmitting disease.

‘Zydus Cadila COVID-19 vaccine found safe in phase I and II clinical trials.’

The phase II study of the vaccine ZyCoV-D had been conducted in over 1,000 healthy adult volunteers as part of the adaptive phase I/II dose escalation, multi-centric, randomised, double-blind placebo controlled study. The vaccine was found to be safe and immunogenic.

The trial has been reviewed by an independent Data Safety Monitoring Board (DSMB) and reports have been submitted to Central Drugs Standard Control Organisation (CDSCO) regularly for the update on safety outcome.

Pankaj R. Patel, Chairman of the Zydus Group said, "After establishing safety in phase I clinical trial, ZyCoV-D has now completed Phase II clinical trials and the vaccine has been found to be safe and immunogenic. We are optimistic of phase III clinical trial outcomes as well and that we would be able to start production of the novel vaccine on its successful completion."

COVID-19 Vaccine Market Dashboard Launched: UNICEF
UNICEF has announced the launch of a COVID-19 vaccine market dashboard. It is an interactive tool that provides a regularly updated overview of the global research and development.

With ZyCoV-D, the company has successfully established the DNA vaccine platform in the country, a statement said.

The platform is also known to show much improved vaccine stability thus requiring lower cold chain requirements. This makes the vaccine ideal for access in remotest regions of the country. Administered through the intradermal route, it also allows for ease of administration. Further, the platform also provides ease of manufacturing the vaccine with minimal biosafety requirements (BSL-1). Furthermore, the platform can be rapidly used to modify the vaccine in a couple of weeks in case the virus mutates to ensure that the vaccine still elicits protection.

European Union Approves the Usage of COVID-19 Vaccine
Hours after the European Medicines Agency (EMA) made a positive scientific assessment, the European Union (EU) has approved the usage of the Pfizer/BioNTech vaccine against the novel coronavirus.

The plasmid DNA when introduced into the host cells would be translated into the viral protein and will elicit a strong immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance. Zydus acknowledges the support of National Biopharma Mission, BIRAC, Department of Biotechnology, ICMR and NIV Pune in the development of ZyCoV-D.

Source-IANS

Effects of COVID-19 Vaccine and Male Fertility
New study sheds light on the impact of the COVID-19 vaccine on male fertility. Study has confirmed that the COVID-19 virus can affect sperm production inside the testes.